You can buy or sell MGTA and other stocks, options, ETFs, and crypto commission-free!
Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. Read More It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 6
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $13.25 per share. The tota...
-$0.57 per share
-$0.44 per share